WO1999046379A3 - Proteines receptrices humaines; reactifs et procedes associes - Google Patents

Proteines receptrices humaines; reactifs et procedes associes Download PDF

Info

Publication number
WO1999046379A3
WO1999046379A3 PCT/US1999/003735 US9903735W WO9946379A3 WO 1999046379 A3 WO1999046379 A3 WO 1999046379A3 US 9903735 W US9903735 W US 9903735W WO 9946379 A3 WO9946379 A3 WO 9946379A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
receptor proteins
human receptor
related reagents
reagents
Prior art date
Application number
PCT/US1999/003735
Other languages
English (en)
Other versions
WO1999046379A2 (fr
Inventor
Christi L Parham
Kevin W Moore
Nicholas J Murgolo
J Fernando Bazan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to AU28718/99A priority Critical patent/AU2871899A/en
Priority to JP2000535746A priority patent/JP2002505879A/ja
Priority to EP99909534A priority patent/EP1062332A2/fr
Priority to CA002323236A priority patent/CA2323236A1/fr
Publication of WO1999046379A2 publication Critical patent/WO1999046379A2/fr
Publication of WO1999046379A3 publication Critical patent/WO1999046379A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des acides nucléiques codant pour des protéines réceptrices purifiées de mammifères, comme les rongeurs ou les primates, et des fragments de celles-ci. L'invention porte aussi sur des anticorps, polyclonaux et monoclonaux, ainsi que sur des procédés d'utilisation desdites compositions à des fins diagnostiques et thérapeutiques.
PCT/US1999/003735 1998-03-09 1999-03-08 Proteines receptrices humaines; reactifs et procedes associes WO1999046379A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU28718/99A AU2871899A (en) 1998-03-09 1999-03-08 Human receptor proteins; related reagents and methods
JP2000535746A JP2002505879A (ja) 1998-03-09 1999-03-08 ヒトレセプタータンパク質；関連する試薬および方法
EP99909534A EP1062332A2 (fr) 1998-03-09 1999-03-08 Proteines receptrices humaines; reactifs et procedes associes
CA002323236A CA2323236A1 (fr) 1998-03-09 1999-03-08 Proteines receptrices humaines; reactifs et procedes associes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3739498A 1998-03-09 1998-03-09
US09/037,394 1998-03-09

Publications (2)

Publication Number Publication Date
WO1999046379A2 WO1999046379A2 (fr) 1999-09-16
WO1999046379A3 true WO1999046379A3 (fr) 1999-10-21

Family

ID=21894109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003735 WO1999046379A2 (fr) 1998-03-09 1999-03-08 Proteines receptrices humaines; reactifs et procedes associes

Country Status (5)

Country Link
EP (1) EP1062332A2 (fr)
JP (1) JP2002505879A (fr)
AU (1) AU2871899A (fr)
CA (1) CA2323236A1 (fr)
WO (1) WO1999046379A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60030769T2 (de) 1999-12-23 2007-10-25 Zymogenetics, Inc., Seattle Verfahren zur behandlung von entzündungen
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
JP4741139B2 (ja) * 1999-12-23 2011-08-03 ザイモジェネティクス， インコーポレイテッド 可溶性インターロイキン−２０レセプター
US7122632B2 (en) 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
EP1294888B1 (fr) 2000-06-30 2007-04-25 ZymoGenetics, Inc. Proteine zcyto21de type interferon
JP5015404B2 (ja) 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド 可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
EP1803733B1 (fr) 2000-09-15 2010-03-10 ZymoGenetics, Inc. Polypeptides comprenant le domaine extracellulaire de IL-20RA et / ou IL-20RB
US6902930B2 (en) * 2001-08-29 2005-06-07 Vanderbilt University Human Mob-5 (IL-24) receptors and uses thereof
US7582287B2 (en) 2001-12-17 2009-09-01 Zymogenetics, Inc. Method for treating cervical cancer
BRPI0408705A (pt) 2003-03-24 2006-03-07 Zymogenetics Inc método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20
EP1927600A1 (fr) 2003-08-07 2008-06-04 Zymogenetics, Inc. Propositions homogènes de IL-28 et IL-29
WO2005052001A2 (fr) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anticorps du recepteur anti-il-20 et partenaires de liaison et procedes d'utilisation dans l'inflammation
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
CN107693791B (zh) 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
AU2011257219B2 (en) 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005847A1 (fr) * 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Fonction du facteur accessoire de l'interferon gamma et de son recepteur
WO1995016036A2 (fr) * 1993-12-09 1995-06-15 Michel Aguet CHAINE β DE RECEPTEURS D'IFN-η ET LEURS DERIVES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005847A1 (fr) * 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Fonction du facteur accessoire de l'interferon gamma et de son recepteur
WO1995016036A2 (fr) * 1993-12-09 1995-06-15 Michel Aguet CHAINE β DE RECEPTEURS D'IFN-η ET LEURS DERIVES

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002112563, Database accession no. AA455558 *
HEMMI S. ET AL.: "A novel member of the Interferon Receptor family complements functionality of the murine Interferon gamma Receptor in human cells", CELL, vol. 76, 11 March 1994 (1994-03-11), pages 803 - 810, XP002112561 *
PESTKA S.: "The Interferon Receptors", SEMINARS IN ONCOLOGY, vol. 24, no. 3 suppl. 9, June 1997 (1997-06-01), pages S9-18 - S9-40, XP002113151 *
SOH J. ET AL.: "Identification and sequence of an accessory factor required for activation of the human Interferon gamma Receptor", CELL, vol. 76, 11 March 1994 (1994-03-11), pages 793 - 802, XP002067347, ISSN: 0092-8674 *
ZUKER C. ET AL.: "Dictyostelium transposable element DIRS-1 has 350-base-pair inverted terminal repeats that contain a heat shock promoter", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 81, May 1984 (1984-05-01), pages 2660 - 2664, XP002112562 *

Also Published As

Publication number Publication date
EP1062332A2 (fr) 2000-12-27
AU2871899A (en) 1999-09-27
CA2323236A1 (fr) 1999-09-16
WO1999046379A2 (fr) 1999-09-16
JP2002505879A (ja) 2002-02-26

Similar Documents

Publication Publication Date Title
WO2002020569A3 (fr) Genes mammaliens, reactifs et methodes associes
WO2001090358A3 (fr) Proteines de recepteurs de mammiferes, reactifs et procedes apparentes
AU6135101A (en) Mammalian receptor proteins; related reagents and methods
ZA200604026B (en) IL-23 and its receptor ; related reagents and methods
EP1433792A8 (fr) Protéines réceptrices humaines, réactifs et méthodes associés
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
WO2001036467A3 (fr) Proteines de recepteurs mammaliens, reactifs et procedes s'y rapportant
EP2292760A3 (fr) Cytokines de mammifères, récepteurs, réactifs correspondants et méthodes
WO1999046379A3 (fr) Proteines receptrices humaines; reactifs et procedes associes
DE69836630D1 (de) Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
WO2001057219A3 (fr) Cytokines mammaliennes, leurs recepteurs, reactifs et procedes correspondants
NZ515382A (en) OX2 receptor homologs
WO2005065711A3 (fr) Proteines de recepteurs de mammiferes, reactifs et procedes associes
WO1999019480A3 (fr) Proteines receptrices humaines et reactifs et methodes associes
WO2000017363A3 (fr) MOLECULE DU TYPE INTERLEUKINE-1: INTERLEUKINE-1z, ACIDES NUCLEIQUES, POLYPEPTIDES, ANTICORPS ET LEURS APPLICATIONS
WO2001046419A3 (fr) Proteines mammaliennnes, reactifs et procedes associes
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 535746

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2323236

Country of ref document: CA

Ref country code: CA

Ref document number: 2323236

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/008848

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999909534

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999909534

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1999909534

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999909534

Country of ref document: EP